Revlimid Capsule
Product Images NDC 59572-420

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Revlimid (NDC 59572-420). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 01

Revlimid 2.5 mg capsules label showing proprietary and generic names (lenalidomide), dosage strength of 2.5 mg per capsule, manufacturer Celgene Corporation, packaging count of 28 capsules, and a boxed warning about potential for human birth defects. The label includes storage instructions and FDA-required barcode and NDC number 59572-402-28.*

FDA Label Image

Image 02

Revlimid 5 mg capsules label showing the product name with active ingredient lenalidomide, strength 5 mg, and package count of 28 capsules. Label includes storage instructions, a warning about potential human birth defects, Rx only designation, and manufacturer information for Celgene Corporation in Summit, NJ. Barcode is also visible.*

FDA Label Image

Image 03

Label for Revlimid (lenalidomide) capsules, 10 mg strength, containing 28 capsules. The label includes storage instructions, manufacturer information (Celgene Corporation, Summit, NJ), a warning about potential human birth defects, and a barcode.*

FDA Label Image

Image 04

Label for Revlimid 15 mg (lenalidomide) oral capsules by Celgene Corporation. The label displays the product name, strength, quantity of 21 capsules, NDC code 59572-415-21, storage instructions, and a warning about potential human birth defects. The barcode and manufacturer details are also shown.*

FDA Label Image

Image 05

Revlimid (lenalidomide) capsules 20 mg oral dosage form in a package containing 21 capsules. The label includes a warning about potential human birth defects and states 'Rx only.' Manufactured for Celgene Corporation, with storage instructions and barcode visible.*

FDA Label Image

Image 06

Revlimid (lenalidomide) capsules 25 mg label for a 21-capsule package by Celgene Corporation. The label includes NDC 59572-425-21, a warning about potential human birth defects, storage instructions at 20°C-25°C with allowed excursions, manufacturer information in Summit, NJ, and a barcode.*

FDA Label Image

Chemical Structure (Revlimid 01)

Chemical structure of Lenalidomide, the active ingredient in Revlimid. The diagram shows the molecular arrangement commonly used in pharmaceutical identification and study.*

FDA Label Image

Kaplan-meier Curves Of Progression-free Survival Based On Irac Assessment (itt Population) (Revlimid 02)

A progression-free survival Kaplan-Meier curve comparing three treatment groups labeled Rd Continuous, Rd18, and MPT. The x-axis shows progression-free survival in months, while the y-axis shows survival probability percentage. A table below displays the number of subjects at risk over time for each treatment group. Additional statistical values including hazard ratios and a logrank p-value are presented within the chart.*

FDA Label Image

Kaplan-meier Curves Of Overall Survival (itt Population) (Revlimid 03)

A Kaplan-Meier overall survival probability graph showing survival over time (months) for three treatment groups: Rd Continuous, Rd18, and MPT. The y-axis represents survival probability percentage, and the x-axis shows time in months. A table below the graph lists the number of subjects at risk for each group at several time points, along with hazard ratios and confidence intervals comparing the groups.*

FDA Label Image

Kaplan-meier Curves Of Progression-free Survival From Randomization (itt Post-asct Population) In Maintenance Study 1 (Revlimid 04)

Kaplan-Meier progression-free survival curve comparing Lenalidomide (blue line) versus placebo (red dashed line). The x-axis represents time in months, and the y-axis shows the proportion of subjects progression-free. The graph includes number of subjects at risk over time and hazard ratio statistics for Lenalidomide versus placebo.*

FDA Label Image

Kaplan-meier Curves Of Progression-free Survival From Randomization (itt Post-asct Population) In Maintenance Study 2 (Revlimid 05)

A Kaplan-Meier survival curve chart comparing progression-free survival (months) between Lenalidomide and placebo groups. The chart shows survival probability on the y-axis and progression-free survival time in months on the x-axis, with separate curves for Lenalidomide (blue solid line) and placebo (red dashed line). A table below shows the number of subjects at risk at different time points and progression-free survival event counts for both groups.*

FDA Label Image

Kaplan-meier Estimate Of Time To Progression (Study 1)

A Kaplan-Meier survival curve graph comparing the proportion of subjects over time to progression (in months) between two treatment groups: Revlimid/Dex and Placebo/Dex. The graph includes hazard ratio (HR) with 95% confidence interval (CI) and a log-rank p-value indicating statistical significance.*

FDA Label Image

Kaplan-meier Estimate Of Time To Progression (Study 2)

A Kaplan-Meier survival curve graph showing the proportion of subjects over time to progression (months). Two lines compare Revlimid/Dex with Placebo/Dex in a clinical study, with the Revlimid/Dex group showing a higher proportion of subjects remaining without progression over time. The graph includes statistical values such as hazard ratio and log-rank p-value.*

FDA Label Image

Revlimid 07a

A Kaplan-Meier survival curve chart showing progression-free survival probability over months. The chart compares two groups: Rituximab plus Lenalidomide versus Rituximab plus Placebo. Survival probability is plotted on the vertical axis, and progression-free survival in months on the horizontal axis. A risk table displays the number of subjects at risk at various time points below the chart.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.